Conexeu Sciences holder exercises 400K warrants
Rhea-AI Filing Summary
Conexeu Sciences Inc. insider entity N3GU Investments LLC, over which reporting person Michael G. Wright has sole voting and dispositive power, exercised 400,000 Performance Warrants to acquire 400,000 shares of Common Stock at $0.001 per share, all held indirectly.
Following the transactions, N3GU Investments LLC indirectly held 1,898,048 shares of Common Stock and 500,000 remaining Performance Warrants. The original grant covered 900,000 Performance Warrants, with future vesting tied to an >$80,000,000 market capitalization milestone and submission of a 510(k) application to the U.S. Food and Drug Administration.
Positive
- None.
Negative
- None.
Insider Trade Summary
400,000 shares exercised/converted
Exercise
2 txns
Insider
Wright Michael G.
Role
10% Owner
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Performance Warrants | 400,000 | $0.00 | $0.00 |
| Exercise | Common Stock | 400,000 | $0.001 | $400.00 |
Holdings After Transaction:
Performance Warrants — 500,000 contracts (Indirect, N3GU Investments LLC);
Common Stock — 1,898,048 shares (Indirect, N3GU Investments LLC)
Footnotes (2)
- F1. The reported securities are held directly by N3GU Investments LLC, a Wyoming limited liability company, over which the Reporting Person has sole voting and dispositive power.
- F2. 900,000 Performance Warrants were granted on June 5, 2025. The Performance Warrants were granted for services rendered to the Issuer and no price was paid for the Performance Warrants. 400,000 Performance Warrants have vested. The remainder of the Performance Warrants will vest and be exercisable upon the following milestone events: (i) 250,000 Performance Warrants upon the Issuer's listed shares of common stock trading for at least 20 consecutive trading days at a market capitalization of >$80,000,000 in the currency of the recognized stock exchange in North America on which the shares of common stock are listed; and (ii) 250,000 Performance Warrants upon the Issuer's submitting a 510(k) application to the United States Food and Drug Administration.
Key Figures
Common shares acquired: 400,000 shares
Exercise price: $0.001/share
Shares held after: 1,898,048 shares
+4 more
7 metrics
Common shares acquired
400,000 shares
Exercised from Performance Warrants at $0.001 per share on May 26, 2026
Exercise price
$0.001/share
Price to exercise Performance Warrants into Common Stock
Shares held after
1,898,048 shares
Indirect Common Stock holdings following the transactions
Performance Warrants granted
900,000 warrants
Granted June 5, 2025 for services rendered to the issuer
Performance Warrants remaining
500,000 warrants
Outstanding after exercise of 400,000 vested warrants
Market cap vesting trigger
>$80,000,000
Market capitalization required for 250,000 warrants to vest
FDA filing milestone
510(k) application
Submission triggers vesting of 250,000 Performance Warrants
Key Terms
Performance Warrants, market capitalization, 510(k) application, voting and dispositive power, +1 more
5 terms
Performance Warrants financial
"900,000 Performance Warrants were granted on June 5, 2025."
market capitalization financial
"trading for at least 20 consecutive trading days at a market capitalization of >$80,000,000"
Market capitalization is the total market value of a company’s outstanding shares, calculated by multiplying the current share price by the number of shares issued. It gives a quick snapshot of a company’s size and how investors value it, influencing perceived risk, index membership, and roughly how much it might cost to buy the whole company — like using a sticker price to compare the relative size and price of different houses.
510(k) application regulatory
"upon the Issuer's submitting a 510(k) application to the United States Food and Drug Administration."
A 510(k) application is a regulatory submission to the U.S. Food and Drug Administration showing that a new medical device is substantially similar to an already approved device, so it can be cleared for marketing without the longest, most rigorous approval process. For investors, a cleared 510(k) means faster, lower-cost market access and lower regulatory risk compared with full approvals, which can speed revenue and reduce uncertainty — like getting permission to sell a new model because it’s close to an existing one.
voting and dispositive power financial
"over which the Reporting Person has sole voting and dispositive power."
indirect ownership financial
"ownership_type": "indirect""
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Conexeu Sciences (CNXU) report in this Form 4?
Conexeu Sciences reported that N3GU Investments LLC exercised 400,000 Performance Warrants to acquire 400,000 shares of Common Stock at $0.001 per share. The holdings are indirect, with reporting person Michael G. Wright having sole voting and dispositive power over the LLC’s securities.
What are Conexeu Sciences (CNXU) Performance Warrants and how many remain?
Conexeu Sciences granted 900,000 Performance Warrants for services, allowing acquisition of Common Stock at a $0.001 exercise price. After exercising 400,000 vested warrants in this filing, 500,000 Performance Warrants remain outstanding and indirectly held by N3GU Investments LLC, subject to future vesting milestones.
What vesting milestones apply to Conexeu Sciences (CNXU) remaining Performance Warrants?
The remaining Performance Warrants vest in two 250,000‑warrant tranches. One vests if Conexeu’s common stock trades for 20 consecutive days at a market capitalization above $80,000,000. The other vests upon the company submitting a 510(k) application to the U.S. Food and Drug Administration.
AI-generated analysis. How Rhea-AI works. Not financial advice.
